Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista Ciências em Saúde |
Texto Completo: | https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040 |
Resumo: | Objective: To describe the occurrence of oral mucositis (OM) in women undergoing cancer treatment for breast cancer (BC). Methods: This is a retrospective, quantitative, and analytical study in medical records of women diagnosed with BC in an oncology service. Clinical data were collected regarding the occurrence and severity of OM according to the World Health Organization criteria and the cancer treatment experienced by the participants. Results: 196 women were included. Of these, 97 (49.5%) developed OM, 43.4% of which were grade 1 or 2 (low or moderate). The occurrence was higher in white women (OR 1.93; 95% CI 1.04 - 3.57; p = 0.035), with metastatic breast cancer (OR 5.46; 95% CI 1.79 - 16.64; p = 0.002) and who experienced taxane agents at some point during chemotherapy (OR 2.26; 95% CI 1.12 - 4.56; p = 0.02). The mean severity of OM in the entire sample was 0.8 ± 1.0, and in the affected women was 1.7 ± 0.7. The difference in the severity of OM by the variables was observed only among women with grade 2 and grade 3 fatigue (p = 0.03). Conclusions: OM is a common mucocutaneous toxicity in women with BC. Despite the low severity observed, care for women with BC undergoing cancer treatment must consider the possible risks and complications associated with OM, adopting strategies to prevent, monitor, and treat them. |
id |
RCS_a23e635bd9f41b99dd6591a78c7da905 |
---|---|
oai_identifier_str |
oai:ojs.portalrcs.hcitajuba.org.br:article/1040 |
network_acronym_str |
RCS |
network_name_str |
Revista Ciências em Saúde |
repository_id_str |
|
spelling |
Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian NortheastOcorrência de mucosite oral em mulheres durante tratamento oncológico de câncer de mama no Nordeste brasileirobreast neoplasmsepidemiologyoral mucositisStomatitisoral mucositisbreast neoplasmepidemiologiamucosite oralneoplasias da mamaestomatitemucosite oralcâncer de mamaObjective: To describe the occurrence of oral mucositis (OM) in women undergoing cancer treatment for breast cancer (BC). Methods: This is a retrospective, quantitative, and analytical study in medical records of women diagnosed with BC in an oncology service. Clinical data were collected regarding the occurrence and severity of OM according to the World Health Organization criteria and the cancer treatment experienced by the participants. Results: 196 women were included. Of these, 97 (49.5%) developed OM, 43.4% of which were grade 1 or 2 (low or moderate). The occurrence was higher in white women (OR 1.93; 95% CI 1.04 - 3.57; p = 0.035), with metastatic breast cancer (OR 5.46; 95% CI 1.79 - 16.64; p = 0.002) and who experienced taxane agents at some point during chemotherapy (OR 2.26; 95% CI 1.12 - 4.56; p = 0.02). The mean severity of OM in the entire sample was 0.8 ± 1.0, and in the affected women was 1.7 ± 0.7. The difference in the severity of OM by the variables was observed only among women with grade 2 and grade 3 fatigue (p = 0.03). Conclusions: OM is a common mucocutaneous toxicity in women with BC. Despite the low severity observed, care for women with BC undergoing cancer treatment must consider the possible risks and complications associated with OM, adopting strategies to prevent, monitor, and treat them.Objetivo: Descrever a ocorrência de mucosite oral (MO) em mulheres em tratamento oncológico para câncer de mama (CM). Métodos: Trata-se de um estudo retrospectivo, quantitativo e analítico em prontuários de mulheres com diagnóstico de CM em um serviço de oncologia. Dados clínicos foram coletados quanto à ocorrência e gravidade da MO de acordo com os critérios da Organização Mundial da Saúde e o tratamento oncológico vivenciado pelas participantes. Resultados: Foram incluídas 196 mulheres. Destas, 97 (49,5%) desenvolveram MO, sendo 43,4% grau 1 ou 2 (baixo ou moderado). A ocorrência foi maior em mulheres brancas (OR 1,93; IC95% 1,04 – 3,57; p = 0,035), com câncer de mama metastático (OR 5,46; IC95% 1,79 – 16,64; p = 0,002) e que experimentaram agentes taxanos em algum momento da quimioterapia (OR 2,26; IC95% 1,12 – 4,56; p = 0,02). A gravidade média da MO em toda a amostra foi de 0,8 ± 1,0 e nas mulheres afetadas foi de 1,7 ± 0,7. Diferença na gravidade da MO pelas variáveis foi observada apenas entre as mulheres com fadiga grau 2 e grau 3 (p = 0,03). Conclusões: MO é uma toxicidade mucocutânea comum em mulheres com CM. Apesar da baixa gravidade observada, o cuidado à mulher com CM em tratamento oncológico deve considerar os possíveis riscos e complicações associadas à MO, adotando estratégias para prevenir, monitorar e tratá-las.AISI/HCI2020-12-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer reviewedAvaliado pelos parestextoinfo:eu-repo/semantics/otherapplication/pdftext/xmltext/htmlhttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/104010.21876/rcshci.v10i4.1040Revista Ciências em Saúde; v. 10 n. 4 (2020): Outubro a Dezembro de 2020; 144-150Health Sciences Journal; Vol 10 No 4 (2020): October to December 2020; 144-1502236-378510.21876/rcshci.v10i4reponame:Revista Ciências em Saúdeinstname:Hospital de Clínicas de Itajubáinstacron:HCIenghttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/626https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/632https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/650Copyright (c) 2020 Revista Ciências em Saúdehttps://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessBarbosa-Lima, RicardoKameo, Simone YurikoAmorim, Bruno FerreiraRamos, Maria Júlia OliveiraCosta, Jéssica dos SantosMarinho, Pabliane Matias LordeloSawada, Namie OkinoMoura Silva, Glebson2021-01-07T17:10:14Zoai:ojs.portalrcs.hcitajuba.org.br:article/1040Revistahttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zeroPUBhttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/oaircs@hcitajuba.org.br||rcsfmit@medicinaitajuba.com.br2236-37852236-3785opendoar:2021-01-07T17:10:14Revista Ciências em Saúde - Hospital de Clínicas de Itajubáfalse |
dc.title.none.fl_str_mv |
Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast Ocorrência de mucosite oral em mulheres durante tratamento oncológico de câncer de mama no Nordeste brasileiro |
title |
Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast |
spellingShingle |
Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast Barbosa-Lima, Ricardo breast neoplasms epidemiology oral mucositis Stomatitis oral mucositis breast neoplasm epidemiologia mucosite oral neoplasias da mama estomatite mucosite oral câncer de mama |
title_short |
Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast |
title_full |
Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast |
title_fullStr |
Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast |
title_full_unstemmed |
Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast |
title_sort |
Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast |
author |
Barbosa-Lima, Ricardo |
author_facet |
Barbosa-Lima, Ricardo Kameo, Simone Yuriko Amorim, Bruno Ferreira Ramos, Maria Júlia Oliveira Costa, Jéssica dos Santos Marinho, Pabliane Matias Lordelo Sawada, Namie Okino Moura Silva, Glebson |
author_role |
author |
author2 |
Kameo, Simone Yuriko Amorim, Bruno Ferreira Ramos, Maria Júlia Oliveira Costa, Jéssica dos Santos Marinho, Pabliane Matias Lordelo Sawada, Namie Okino Moura Silva, Glebson |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Barbosa-Lima, Ricardo Kameo, Simone Yuriko Amorim, Bruno Ferreira Ramos, Maria Júlia Oliveira Costa, Jéssica dos Santos Marinho, Pabliane Matias Lordelo Sawada, Namie Okino Moura Silva, Glebson |
dc.subject.por.fl_str_mv |
breast neoplasms epidemiology oral mucositis Stomatitis oral mucositis breast neoplasm epidemiologia mucosite oral neoplasias da mama estomatite mucosite oral câncer de mama |
topic |
breast neoplasms epidemiology oral mucositis Stomatitis oral mucositis breast neoplasm epidemiologia mucosite oral neoplasias da mama estomatite mucosite oral câncer de mama |
description |
Objective: To describe the occurrence of oral mucositis (OM) in women undergoing cancer treatment for breast cancer (BC). Methods: This is a retrospective, quantitative, and analytical study in medical records of women diagnosed with BC in an oncology service. Clinical data were collected regarding the occurrence and severity of OM according to the World Health Organization criteria and the cancer treatment experienced by the participants. Results: 196 women were included. Of these, 97 (49.5%) developed OM, 43.4% of which were grade 1 or 2 (low or moderate). The occurrence was higher in white women (OR 1.93; 95% CI 1.04 - 3.57; p = 0.035), with metastatic breast cancer (OR 5.46; 95% CI 1.79 - 16.64; p = 0.002) and who experienced taxane agents at some point during chemotherapy (OR 2.26; 95% CI 1.12 - 4.56; p = 0.02). The mean severity of OM in the entire sample was 0.8 ± 1.0, and in the affected women was 1.7 ± 0.7. The difference in the severity of OM by the variables was observed only among women with grade 2 and grade 3 fatigue (p = 0.03). Conclusions: OM is a common mucocutaneous toxicity in women with BC. Despite the low severity observed, care for women with BC undergoing cancer treatment must consider the possible risks and complications associated with OM, adopting strategies to prevent, monitor, and treat them. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-18 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer reviewed Avaliado pelos pares texto info:eu-repo/semantics/other |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040 10.21876/rcshci.v10i4.1040 |
url |
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040 |
identifier_str_mv |
10.21876/rcshci.v10i4.1040 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/626 https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/632 https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/650 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Revista Ciências em Saúde https://creativecommons.org/licenses/by-nc-sa/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Revista Ciências em Saúde https://creativecommons.org/licenses/by-nc-sa/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf text/xml text/html |
dc.publisher.none.fl_str_mv |
AISI/HCI |
publisher.none.fl_str_mv |
AISI/HCI |
dc.source.none.fl_str_mv |
Revista Ciências em Saúde; v. 10 n. 4 (2020): Outubro a Dezembro de 2020; 144-150 Health Sciences Journal; Vol 10 No 4 (2020): October to December 2020; 144-150 2236-3785 10.21876/rcshci.v10i4 reponame:Revista Ciências em Saúde instname:Hospital de Clínicas de Itajubá instacron:HCI |
instname_str |
Hospital de Clínicas de Itajubá |
instacron_str |
HCI |
institution |
HCI |
reponame_str |
Revista Ciências em Saúde |
collection |
Revista Ciências em Saúde |
repository.name.fl_str_mv |
Revista Ciências em Saúde - Hospital de Clínicas de Itajubá |
repository.mail.fl_str_mv |
rcs@hcitajuba.org.br||rcsfmit@medicinaitajuba.com.br |
_version_ |
1797068962841755648 |